[Pregnancies associated with valvular prosthesis at Dakar Teaching Hospital: prognosis, epidemiological, clinical and therapeutical aspects].
OBJECTIVE
The persistence of the rheumatic valvular cardiopathie and the access to cardiac surgery make this association frequent. This work will deal with a description of the epidemiological and clinic profile and the evaluation of the cares to the pregnancies with cardiac valvular prostheses.


METHODS
We took a retrospective study beginning from 1987 to 2006 about 14 cases, which had benefited from collaboration between the Gynaecologic and Obstetric Clinic and the Cardiological Clinic of the University Hospital Center of Dakar.


RESULTS
The frequency of pregnancies with valvular prosthesis was of 0.12 per thousand. The average age of our patients was of 27.7 years. The average pregnancy was of 2.3 gestures with extremes of 1st to 12th gestures. The pregnancies were not, in any case, planned. An auricular fibrillation was noticed in four patients. The fraction of ejection of the left ventricle was superior or equal to 60% in 10 cases, the prosthesis was lightly blocked in two cases. Despite the use of anti-vitamin K during the first trimester with 42.86% of the patients, the anticoagulation was effective with the entire cases excepted one who died by lung embolism. The delivery was, in seven cases, realized by caesarean and in two cases by natural way. Two cases of premature and foetal hypotrophy have been noticed. There was no case of malformed children.


CONCLUSIONS
With a multidisciplinary care, the carry of valvular prosthesis can be compatible with pregnancy. The lack of embryopathy and malformed children could incite to propose the oral anticoagulation during the whole sequence of pregnancy.
Mbaye
M
M
Clinique gynécologique et obstétricale, université Cheikhe-Anta-Diop, CHU Aristide-le-Dantec, BP 3001, Dakar, Sénégal. magatte4@yahoo.fr
Moreira
P-M
PM
Guèye
S M K
SM
Cissé
C T
CT
Moreau
J-C
JC
Kane
A
A
Diao
M
M
D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006349:Heart Valve Diseases / Q000601:surgery; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006801:Humans; D007231:Infant, Newborn; D008943:Mitral Valve / Q000601:surgery; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000453:epidemiology* / Q000401:mortality; D011256:Pregnancy Outcome; D018873:Pregnancy Rate; D018566:Pregnancy, High-Risk; D011379:Prognosis; D011475:Prosthesis Failure; D012189:Retrospective Studies; D012307:Risk Factors; D012675:Senegal / Q000453:epidemiology; D015996:Survival Rate; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D014261:Tricuspid Valve / Q000601:surgery
D000925:Anticoagulants